PRNewswire

Syndax Pharmaceuticals, Inc., a late-stage epigenetics oncology company, announced today that members of management will present at the following upcoming fall conferences:

• BIO Investor Forum, San Francisco, CA, October 25 at 1:30 PM PT
• 9th International Discovery on Target, Panel Discussion: HDACi and Their Progress in the Clinic, Boston, MA, November 3, 10:40 AM ET
• Lazard Annual Healthcare Conference, New York, NY, November 16, 1:30 PM ET
• Life Sciences Summit, New York, NY, November 17, 4:15 PM ET  

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, late-stage, oncology-focused pharmaceutical company. The company is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax has worldwide rights to develop and commercialize entinostat which has shown promise in randomized clinical trials in solid tumors. Syndax is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. Formed in 2005, Syndax’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.     For more information please visit www.syndax.com.